8-KOther EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Dec 11, 2006)

Filed December 11, 2006For Securities:PFE

Summary

This 8-K filing from Pfizer Inc. (PFE), dated December 11, 2006, primarily serves to provide financial information in a newly adopted XBRL (eXtensible Business Reporting Language) format. The filing includes unaudited financial data from Pfizer's Quarterly Report on Form 10-Q for the quarter ended October 1, 2006, specifically the Condensed Consolidated Statements of Income, Balance Sheets, and Statements of Cash Flows. It is crucial for investors to understand that this filing is part of an SEC voluntary XBRL pilot program. The XBRL data is explicitly stated as unaudited and not the official financial statements. Investors are advised to continue relying on the officially filed versions of financial documents for making investment decisions, as the information presented in this 8-K is for testing technological formats and should not be used for liability purposes under Section 18 of the Exchange Act.

Key Highlights

  • 1Pfizer is participating in the SEC's voluntary XBRL pilot program.
  • 2The filing furnishes unaudited financial information from Pfizer's Q3 2006 10-Q filing in XBRL format.
  • 3Key financial statements included are Income Statements, Balance Sheets, and Cash Flow Statements for relevant periods in 2006 and 2005.
  • 4Investors are strongly cautioned that this XBRL data is not the official filing and should not be relied upon for investment decisions.
  • 5The XBRL data is for testing the XBRL format and technology, not for official reporting or liability.
  • 6Information in this 8-K is not deemed 'filed' for Section 18 of the Exchange Act and has limited liability implications.
  • 7The filing includes various XBRL-related documents such as Instance, Schema, Calculation, Label, and Presentation linkbase files.

Frequently Asked Questions

The primary purpose of this 8-K filing is to provide Pfizer's financial information from its Q3 2006 10-Q report in XBRL format as part of the SEC's voluntary XBRL pilot program. This allows the SEC and participants to test the XBRL technology and reporting format.

No, investors are strongly advised against making investment decisions based on the XBRL data provided in this 8-K. The filing explicitly states that the XBRL information is unaudited, not the official financial statements, and is for testing purposes only. Investors should continue to rely on the officially filed financial statements.

The XBRL-formatted exhibit (Exhibit 100) contains unaudited versions of Pfizer's Condensed Consolidated Statements of Income, Condensed Consolidated Balance Sheets, and Condensed Consolidated Statements of Cash Flows for the periods ended October 1, 2006, and comparative periods in 2005 and 2006.

According to Rule 402 of Regulation S-T, the information in this 8-K, including the XBRL data, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it is not subject to the liability provisions of that section, reinforcing that it's for informational and testing purposes rather than official disclosure.